We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Read MoreHide Full Article
Shares of the large pharmaceutical company Merck & Co. Inc. (MRK - Free Report) were climbing higher Thursday on news that the company’s late-stage lung cancer treatment showed positive results and outperformed traditional chemotherapy. As of around 3 PM ET MRK was up to $57.61, a jump of 2.71% on the day.
Results came back from the Keynote-024 trial where the drug Keytruda was used as the sole treatment of patients with non-small-cell lung cancer. Though Merck & Co. didn’t release any numbers, the company said that the Keynote-024 trial was stopped because it already proved Keytruda’s ability to lengthen progression-free survival and overall survival compared to standard chemotherapy treatments.
The trial studied only patients which had tumors that showed high expression of PD-L1, the ligand that Keytruda is meant to treat through targeting the PD-1 protein. More details regarding the trial are expected to be released at an undisclosed future time.
As it stands the Keytruda drug is only approved to treat relapsed cases of late-stage lung cancer, but the company said it plans to file for a label expansion as soon as it can. The expansion could be a major positive for the company in the company in the coming months, but only time will tell if they are able to get approval from regulators.
Merck & Co. is currently a Zacks Rank #3 (Hold) stock, but any further positive trials or label expansion of the Keytruda drug could change that in the future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Shares of the large pharmaceutical company Merck & Co. Inc. (MRK - Free Report) were climbing higher Thursday on news that the company’s late-stage lung cancer treatment showed positive results and outperformed traditional chemotherapy. As of around 3 PM ET MRK was up to $57.61, a jump of 2.71% on the day.
Results came back from the Keynote-024 trial where the drug Keytruda was used as the sole treatment of patients with non-small-cell lung cancer. Though Merck & Co. didn’t release any numbers, the company said that the Keynote-024 trial was stopped because it already proved Keytruda’s ability to lengthen progression-free survival and overall survival compared to standard chemotherapy treatments.
The trial studied only patients which had tumors that showed high expression of PD-L1, the ligand that Keytruda is meant to treat through targeting the PD-1 protein. More details regarding the trial are expected to be released at an undisclosed future time.
As it stands the Keytruda drug is only approved to treat relapsed cases of late-stage lung cancer, but the company said it plans to file for a label expansion as soon as it can. The expansion could be a major positive for the company in the company in the coming months, but only time will tell if they are able to get approval from regulators.
Merck & Co. is currently a Zacks Rank #3 (Hold) stock, but any further positive trials or label expansion of the Keytruda drug could change that in the future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>